• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Curable initiates the International PSC Genome Project

Curable initiates the International PSC Genome Project

November 18, 2016
CenterWatch Staff

Curable, a nonprofit research accelerator that applies engineering approaches to medicine to develop solutions for rare diseases, has announced the initiation of the International PSC Genome Project, which includes the Regeneron Genetics Center (RGC, a wholly-owned subsidiary of Regeneron Pharmaceuticals) and the Mayo Clinic with the goal of conducting the largest sequencing project for primary sclerosing cholangitis (PSC) to date.

PSC is an autoimmune disease of the bile ducts that leads to liver failure. There are about 50,000 patients with PSC in the U.S. today. No one knows what causes this disease, and there are currently no effective medical therapies.

During this project, the RGC will sequence 5,000 or more PSC patients, as well as samples from healthy volunteers to help identify the genetic underpinnings of PSC. Mayo Clinic is contributing over 3,000 DNA samples from appropriately consented volunteers, including over 1,200 samples from PSC patients. Curable is establishing a coalition of nonprofit institutions to participate in this project and the RGC is bringing its sequencing and analytical capabilities to the table.

“We are excited to be working with Regeneron on this important global project,” said Curable Chief Executive Officer Lisa Boyette, M.D., Ph.D. “At Curable, we firmly believe that it is this type of large-scale collaborative effort that will dramatically accelerate the R&D process. That progress will enable us to deliver the new therapeutics and early diagnostic in phase II clinical trials that we have promised our customers, who are PSC patients, in five years.”

“Through sequencing and genetic analysis, we will be able to learn more about the genetic basis of PSC and hope to uncover actionable findings for drug discovery and genomic medicine,” said Aris Baras, M.D., vice president and co-head of the RGC. “Regeneron’s goal is to advance the development of new and improved medicines for people in need, and working with dedicated organizations like Curable and the Mayo Clinic helps us further this collective mission.”

All of the coalition collaborators and the RGC will be able to analyze the genetic data and publish their findings.

“This focus on awareness, matchmaking, and effectively leveraging resources to achieve transformational solutions for underserved patients is what makes Curable unique,” said Dietrich Stephan, Ph.D., chairman of Curable’s board of directors.

“Curable’s approach—with its PSC coalition—is enabling us to pool samples and undertake a much larger study than any of the member institutions could conduct alone,” added Konstantinos Lazaridis, M.D., consultant in Gastroenterology and Hepatology and Professor of Medicine, Mayo Clinic. “I have been taking care of PSC patients for over 20 years, with no real advances to offer them apart from liver transplantation. I am so pleased that through this kind of data sharing and transparency, we will be able to maximize our efforts and provide PSC patients with tangible insights into the genetic basis of their disease.” 

Curable is bringing together the best resources from academia, industry and the nonprofit sector to benefit PSC patients.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing